CAR-T Market Summary
The CAR-T cell therapy market is expected to grow significantly during the forecast period of 2024–2034, driven by its effectiveness and the potential for broader applications. Collaboration between pharmaceutical companies and research institutions, coupled with ongoing innovations, is likely to contribute to the market’s growth. However, challenges such as manufacturing complexities and pricing considerations may need to be addressed. Chimeric Antigen Receptor-T Cell (CAR-T) therapy is a transformative cancer treatment that harnesses a patient’s immune system to target and eliminate cancer cells, offering a one-time, long-term solution that avoids the toxicity of salvage chemotherapy and autologous transplant, redefining the standard of care for high-risk patients.
Explore DelveInsight’s Full Coverage on the CAR-T Market
CAR-T Cell Therapy Overview
CAR-T cell therapy is a groundbreaking form of immunotherapy designed to treat certain types of blood cancers, including leukemias and lymphomas. The process begins with the collection of a patient’s T cells through a procedure called apheresis. These T cells are then genetically modified in a laboratory to express a Chimeric Antigen Receptor (CAR) that enables them to better recognize and attack cancer cells. After this modification, the CAR-T cells are multiplied and infused back into the patient’s bloodstream, where they seek out and destroy cancerous cells. This therapy has shown promising results, with some patients achieving complete remission even after other treatments have failed. However, CAR-T therapy is not without risks; potential side effects include Cytokine Release Syndrome (CRS) and neurological complications, necessitating close monitoring by specialized medical teams during and after treatment.
CAR-T cell therapies have been involved in treating oncological indications such as multiple myeloma, Acute Myeloid Leukemia (AML), Diffuse Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Peripheral T-cell Lymphoma (PTCL), and others.
CAR-T Market Players
CAR-T companies include:
- Johnson & Johnson Innovative Medicine
- Juno Therapeutics
- Bristol-Myers Squibb
- Kite Pharma (a Gilead company)
- Novartis
- Regeneron Pharmaceuticals
- Arcellx
- BioNTech
- Miltenyi Biomedicine
- Luminary Therapeutics
- Precigen
- Poseida Therapeutics
- And Others
CAR-T Cell Therapy Epidemiology
The CAR-T cell therapy epidemiology chapter provides historical as well as forecasted epidemiology segmented as total incident cases of selected indications for CAR-T cell therapy, total eligible patient pool for CAR-T cell therapy in selected indications, and total treated cases in selected indications for CAR-T cell therapy in the 7MM covering the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan from 2020 to 2034.
Estimated Cases in the US (2024):
- Multiple myeloma: 33,700
- DLBCL: 32,300
- AML: 21,200
- ALL: 6,900
- MCL: 3,500
CAR-T Market Outlook
The CAR-T cell therapy market is expected to grow significantly in the coming years, driven by the increasing number of patients being diagnosed with cancer, growing awareness of CAR-T cell therapies, and the increasing number of CAR-T cell therapies under clinical trials and filed for approval by various companies. KYMRIAH was the first CAR-T therapy approved globally, but YESCARTA became the first to receive FDA approval for DLBCL, in October 2017.
The market is characterized by intense competition and rapid innovation, driven by the need for effective treatments across a spectrum of cancers. A key advantage of CAR-T cell therapies is their one-and-done approach, requiring only a single administration, unlike the continuous treatment needed with bispecific antibodies such as TECVAYLI and TALVEY. The approvals of ABECMA (Bristol-Myers Squibb) and CARVYKTI (Johnson & Johnson Innovative Medicine) highlight the potential of CAR-T cell therapy as a game-changing treatment for multiple myeloma, while emerging players such as Arcellx and Kite Pharma (anitocabtagene autoleucel), Poseida Therapeutics/Roche (P-BCMA-ALLO1), Luminary Therapeutics (LMY-920), and Precigen (PRGN-3006 UltraCAR-T) continue to open new opportunities across the pipeline.
Marketed CAR-T Cell Therapy Drugs
CARVYKTI (ciltacabtagene autoleucel) – Johnson & Johnson Innovative Medicine
CARVYKTI is a BCMA-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adult patients with Relapsed and Refractory Multiple Myeloma (RRMM). It involves reprogramming a patient’s T cells with a transgene encoding a CAR that identifies and eliminates cells expressing BCMA.
- In February 2022, the FDA approved CARVYKTI for adults with multiple myeloma that has relapsed or is refractory to other treatments
- In May 2022, the EMA granted conditional marketing authorization for RRMM patients who have received at least three prior therapies (an IMiD, a proteasome inhibitor, and an anti-CD38 antibody)
- In September 2022, Japan’s MHLW approved CARVYKTI for patients meeting similar prior-therapy criteria
- In April 2024, the US FDA approved the drug for RRMM patients who have received at least one prior line of therapy
YESCARTA (axicabtagene ciloleucel) – Kite Pharma (Gilead Sciences)
YESCARTA is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for adult patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months of it, and for adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL NOS, PMBCL, HGBCL, and DLBCL arising from follicular lymphoma.
- In October 2017, the FDA granted regular approval to YESCARTA
- In August 2018, the European Commission granted marketing authorization for R/R DLBCL and PMBCL after two or more lines of systemic therapy
- In January 2021, Japan’s MHLW approved YESCARTA for certain R/R LBCL patients
- In January 2024, Kite announced FDA approval of a manufacturing process change, reducing median US turnaround time from 16 days to 14 days
Emerging CAR-T Cell Therapy Drugs
Anitocabtagene Autoleucel (anito-cel) – Arcellx and Kite Pharma (A Gilead Company)
Anitocabtagene autoleucel is a cell therapy candidate involving autologous T-cells genetically modified to recognize and kill BCMA-expressing cells, a target antigen for multiple myeloma. It utilizes a D-Domain in place of the traditional scFv binding domain of conventional cell therapies and has been granted Fast Track Designation, Orphan Drug Designation, and Regenerative Medicine Advanced Therapy Designation by the US FDA for RRMM. Kite and Arcellx expanded their collaboration in November 2023 to include lymphomas, and in May 2024 shared the design of iMMagine-3, a global Phase III randomized controlled trial expected to start in the second half of 2025.
Cemacabtagene Ansegedleucel – Allogene Therapeutics
Cemacabtagene ansegedleucel (previously ALLO-501A) is a next-generation anti-CD19 AlloCAR-T investigational product for LBCL. Allogene holds oncology rights in the US, EU, and UK, with options in China and Japan. The pivotal Phase II ALPHA3 trial began in June 2024, evaluating cema-cel as part of first-line treatment consolidation for LBCL patients likely to relapse after standard 1L treatment—the first pivotal trial to offer CAR-T as part of 1L consolidation. Because of this trial’s potential, Allogene has deprioritized its third-line LBCL ALPHA2 and EXPAND trials, and a potential BLA submission is expected in 2027.
CAR-T Cell Therapy Drugs Uptake
This section examines the sales uptake of CAR-T therapies launched or anticipated to launch, estimating market penetration across the US, EU4, the UK, and Japan. Emerging therapies are analyzed on the basis of clinical trial phase, mechanism of action, and indication:
- Anitocabtagene autoleucel (anito-cel) – Arcellx and Kite Pharma – D-domain BCMA-directed CAR-T – Phase III – RRMM
- Zamtocabtagene autoleucel – Miltenyi Biomedicine – Targets combination of CD19 and CD20 – Phase II – DLBCL
- Cemacabtagene ansegedleucel – Allogene Therapeutics – Targets CD19 – Phase II – R/R LBCL
- LMY-920 – Luminary Therapeutics – BAFF-expressing CAR-T cells – Phase I – RRMM/NHL
- PRGN-3006 UltraCAR-T – Precigen – Targeted CD33 elimination – Phase I – CD33-Positive R/R AML
- P-BCMA-ALLO1 – Poseida Therapeutics/Roche – BCMA-targeted CAR-T cells – Phase I – RRMM
- AUTO4 – Autolus – TRBC1-targeting CAR-T cell therapy – Phase I – PTCL
Download the CAR-T Market Report for In-Depth Insights on Pipeline and Forecast
Conclusion
The CAR-T cell therapy market is poised for significant growth through 2034, underpinned by rising cancer diagnoses, growing awareness of CAR-T therapies, and an expanding pipeline advancing toward approval. CARVYKTI continues to lead the multiple myeloma segment following record-breaking sales, while ABECMA remains a strong contender and YESCARTA and KYMRIAH continue to anchor the lymphoma and leukemia segments. With no approved first-line CAR-T therapy yet available, candidates such as cemacabtagene ansegedleucel and anitocabtagene autoleucel could reshape treatment sequencing across multiple indications. As manufacturing efficiencies improve and emerging players such as Arcellx, Allogene, Miltenyi Biomedicine, Luminary Therapeutics, Precigen, and Poseida Therapeutics advance their pipelines, the CAR-T cell therapy market is expected to see substantial transformation and expanded therapeutic access in the coming years.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
